Selina Hummel

Selina Hummel

Auto-generated profile, based on publicly available information

Selina Hummel

Department of Nuclear Medicine, University Hospital of Munich, Ludwig Maximilians University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
LDLina Dinkel
Lina Dinkel
SHSelina Hummel
Selina Hummel
VZValerio Zenatti
Valerio Zenatti
MMMariagiovanna Malara
Mariagiovanna Malara
YTYannik Tillmann
Yannik Tillmann
STSabina Tahirovic
Sabina Tahirovic
Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in the NPC1 gene, causing lipid accumulation within late endosomes/lysosomes and resulting in progressive neurodegeneration. Although microglial activation precedes neuronal loss, it remains elusive whether loss of the membrane protein NPC1 in microglia actively contributes to NPC pathology. In a mouse model with depletion of NPC1 in myeloid cells, we report severe alterations in microglial lipidomic profiles, including the enrichment of bis(monoacylglycero)phosphate, increased cholesterol, and a decrease in cholesteryl esters. Lipid dyshomeostasis was associated with microglial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO). These hyperactive microglia initiated a pathological cascade resembling NPC-like phenotypes, including a shortened life span, motor impairments, astrogliosis, neuroaxonal pathology, and increased neurofilament light chain (NF-L), a neuronal injury biomarker. As observed in the mouse model, patients with NPC showed increased NF-L in the blood and microglial hyperactivity, as visualized by TSPO-PET imaging. Reduced TSPO expression in blood-derived macrophages of patients with NPC was measured after N -acetyl- l -leucine treatment, which has been recently shown to have beneficial effects in patients with NPC, suggesting that TSPO is a potential marker to monitor therapeutic interventions for NPC. Conclusively, these results demonstrate that myeloid dysfunction, driven by the loss of NPC1, contributes to NPC disease and should be further investigated for therapeutic targeting and disease monitoring.

14 April 2022 in Nuklearmedizin-Nuclear Medicine
Verified
Journal Article
Closed access
LSL. Slemann
L. Slemann
SHS. Hummel
S. Hummel
MWM. Willroider
M. Willroider
SRS. Roeber
S. Roeber
TAT. Arzberger
T. Arzberger
LBL. Beyer
L. Beyer
Ziel/Aim Specific binding of [18F]PI-2620 to four-repeat tau has been shown in vivo in patients with progressive supranuclear palsy (PSP), but data on vitro validation is limited. The purpose of this study was to compare the autoradiography signal of cortical formalin-fixed paraffin-embedded brain tissue of the frontal cortex, putamen and pallidum with the immunohistochemical assessed tau load in patients with confirmed PSP. Methodik/Methods We applied [18F]PI-2620 autoradiography to postmortem brain samples (frontal cortex=FCX, putamen, pallidum) of 16 patients with PSP. Brain samples were categorized to two groups with mild and moderate to severe tau pathology, separately for the different brain regions. Autoradiography signal quantification (CWMR=cortex to white matter ratio) was compared between both groups. Ergebnisse/Results Comparing the different brain regions, the relative tracer binding was significantly higher in the basal ganglia regions (putamen+pallidum) when compared to the FCX (CWMRFCX=1.335±0.122, CWMRPutamen=1.452±0.199, CWMRPallidum=1.433±0.144, p=0.006/ 0.016). Patients with a higher amount of cortical tau pathology showed a higher relative tracer binding (p FCX<0.001), whereas there was no difference between groups in the basal ganglia regions (p Putamen=0.180, p Pallidum=0.895). Schlussfolgerungen/Conclusions The relative tracer binding of [18F]PI-2620 reflects the amount of cortical tau pathology in patients with PSP, indicating a specific cortical binding. In the basal ganglia, additional off-target binding may contribute to the autoradiography signal which needs to be further investigated. Publication Date: 14 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

17 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
LWLis de Weerd
Lis de Weerd
SHSelina Hummel
Selina Hummel
SMStephan Alexander Mueller
Stephan Alexander Mueller
IPIñaki Paris
Iñaki Paris
TSThomas Sandmann
Thomas Sandmann
CHChristian Haass
Christian Haass
Anti-amyloid β-peptide (Aβ) immunotherapy was developed to reduce amyloid plaque pathology and slow cognitive decline during progression of Alzheimer’s disease. Efficient amyloid plaque clearance has been proven in clinical trials testing anti-Aβ antibodies, with the impact on cognitive endpoints correlating with the extent of plaque removal. However, treatment is associated with adverse side-effects, such as oedema and haemorrhages, which are potentially linked to the induced immune response. To improve the safety profile of these molecules, it is imperative to understand the consequences of anti-Aβ antibody treatment on immune cell function. Here, we investigated the effects of long-term chronic anti-Aβ treatment on amyloid plaque pathology and microglial response in the APP-SAA triple knock-in mouse model. Mice were treated weekly with anti-Aβ antibody from 4-8 months of age. Long-term treatment with anti-Aβ results in a robust and dose-dependent removal of amyloid plaque pathology, with a higher efficiency for removing diffuse over dense-core plaques. Analysis of the CSF proteome indicates a reduction of markers for neurodegeneration including Tau and α-Synuclein, as well as immune cell related proteins. Bulk RNA-seq revealed a dose-dependent decrease in brain-wide disease-associated microglial (DAM) and glycolytic gene expression, which is supported by a parallel decrease of glucose uptake and protein levels of Triggering receptor of myeloid cells 2 (Trem2) protein, a major immune receptor involved in DAM activation of microglia. In contrast, DAM activation around remaining plaques remains high regardless of treatment dose. In addition, microglia surrounding remaining plaques display a dose-dependent increase in microglial clustering and a selective increase in antigen presenting and immune signalling proteins. These findings demonstrate that long-term chronic anti-Aβ mediated removal of Aβ leads to a dose dependent decrease in brain-wide microglial DAM activation and neurodegeneration, while microglia at residual plaques display a combined DAM and antigen presenting phenotype that suggests a continued treatment response. Abstract Figure: Graphical Schematic overview of the effects of chronic long-term anti-Aβ treatment in APP-SAA mice Schematic was created with BioRender.com